Tumour necrosis factor-alpha infusion produced insulin resistance but no change in the incretin effect in healthy volunteers

Diabetes/Metabolism Research and Reviews

Volumn 29, Issue 8, 2013, Pages 655-663

  Nielsen, Signe Tellerup ^a   Lehrskov Schmidt, Louise ^a   Krogh Madsen, Rikke ^a   Solomon, Thomas P J ^a   Lehrskov Schmidt, Lars ^a   Holst, Jens Juul ^a   Møller, Kirsten ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Glucose; Incretins; Insulin resistance; Systemic inflammation; Tumour necrosis factor alpha

Indexed keywords

C PEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HYDROCORTISONE; INCRETIN; INSULIN; INTERLEUKIN 6; TASONERMIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; CROSSOVER PROCEDURE; FLU LIKE SYNDROME; GLUCOSE TOLERANCE TEST; HORMONE BLOOD LEVEL; HORMONE RESPONSE; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; MALE; NORMAL HUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIDE EFFECT; SYMPTOM;

GLUCOSE; INCRETINS; INSULIN RESISTANCE; SYSTEMIC INFLAMMATION; TUMOUR NECROSIS FACTOR-ALPHA;

ADOLESCENT; ADULT; BLOOD GLUCOSE; C-PEPTIDE; CROSS-OVER STUDIES; CYTOKINES; GLUCOSE TOLERANCE TEST; HEALTHY VOLUNTEERS; HUMANS; HYDROCORTISONE; INCRETINS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; MALE; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84887728995     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2441     Document Type: Article

References (31)

1. http://www.who.int/mediacentre/factsheets/fs312/en/index.html
2. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005; 365: 1333-1346.
3. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29(1): 46-52.
4. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91(1): 301-307.
5. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001; 50(3): 609-613.
6. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 287(2): E199-E206.
7. Kolligs F, Fehmann HC, Goke R, Goke B (1995) Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes 2004; 44(1): 16-19.
8. Zinman B, Hanley AJG, Harris SB, Kwan J, Fantus IG. Circulating tumor necrosis factor-α concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J Clin Endocrinol Metab 1999; 84: 272-278.
9. Plomgaard P, Bouzakri K, Krogh-Madsen R, Mittendorfer B, Zierath JR, Pedersen BK. Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes 2005; 54(10): 2939-2945.
10. Deacon CF, Nauck MA, Meier J, Hücking K, Holst JJ. Degradation of endogenous and exogenous gastric inhibitory polypeptide (GIP) in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 2000; 85: 3575-3581.
11. Ørskov C, Rabenhøj L, Kofod H, Wettergren A, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagons-like peptide-1 in humans. Diabetes 1994; 43: 535-539.
12. Matsuda M, DeFronzo R. Insulin sensitivity indices obtained from oral glucose tolerance testing. Diabetes Care 1999; 22: 1462-1470.
13. Matthews JP, Hosker JP, Rudenski AS, Ba N, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and ß-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologica 1985; 28: 412-419.
14. Eaton RP, Allen RC, Schade DS, Erickson KM, Standefer J. Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behavior. J Clinical Endocrinol Metab 1980; 51(3): 520-528.
15. Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 1992; 41(3): 368-377.
16. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity induced insulin resistance in mice lacking TNF-alpha function. Nature 1997; 389(6651): 610-614.
17. Rask-Madsen C, Dominguez H, Ihlemann N, Hermann T, Kober L, Torp-Pedersen C. Tumor necrosis factor-alpha inhibits insulin's stimulating effect on glucose uptake and endothelium-dependent vasodilation in humans. Circulation 2003; 108: 1815-1821.
18. Kern PA, Ranganathan S, Chungling LI, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001; 280: E745-E751.
19. Pedersen M, Bruunsgaard H, Weis N, et al. Circulating levels of TNF-alpha and IL-6-relation to truncal fat mass and muscle mass in healthy elderly individuals and patients with type 2 diabetes. Mech Ageing Dev 2003; 124: 495-502.
20. Knop FK, Vilsbøll T, Højberg PV, et al. Reduced incretin effect in type 2 diabetes: cause or consequence of diabetic state? Diabetes 2007; 56: 1951-1959.
21. Krogh-Madsen R, Plomgaard P, Moller K, Mittendorfer B, Pedersen BK. Influence of TNF-alpha and IL-6 infusions on insulin sensitivity and expression of IL-18 in humans. Am. J. Physiol Endocrinol. Metab 2006; 291(1): E108-E114.
22. Andersen SK, Gjedsted J, Christiansen C, Tønnesen E. The roles of insulin and hyperglycemia in sepsis pathogenesis. J Leukoc Biol 2003; 75(3): 413-421.
23. Haack M, Reichenberg A, Kraus T, Schuld A, Yirmiya R, Pollmächer T. Effects of an intravenous catheter on the local production of cytokines and soluble cytokine receptors in healthy men. Cytokine 2000; 12(6): 694-698.
24. Maedler K, Sergeev P, Ris F, et al. Glucose-induced beta cell production of IL-1-beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110(6): 851-860.
25. Weaver JR, Holman TR, Imai Y, et al. Integration of pro-inflammatory cytokines, 12-lipooxygenase and NOX-1 in pancreatic islet beta cell dysfunction. Mol Cell Endocrinol 2012; 358: 88-95.
26. Larsen CM, Feulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. New Engl J Med 2007; 356: 1517-1526.
27. Domiguez H, Storgaard H, Rask-Madsen C, et al. Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res 2005; 42: 517-525.
28. Ellingsgaard H, Hauselmann I, Schuler B, et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L-cells and alpha cells. Nat Med 2012; 17(11): 1481-1489.
29. Jensen DH, Aaboe JE, Vølund A, Holst JJ, Madsbad S, Krarup T. Steroid-induced insulin resistance and impaired glucose tolerance are both associated with progressive decline of incretin effect in first-degree relatives of patients with type 2 diabetes. Diabetologica 2012; 55: 1406-1416.
30. Ruzzin J, Wagman AS, Jensen J. Glucocorticoid-induced insulin resistance in skeletal muscle: defects in insulin signalling and the effects of a selective glycogen synthase kinase-3 inhibitor. Diabetologica 2005; 48: 2119-2130.
31. Block NE, Buse MG. Effects of hypercholesterolemia and diabetes on skeletal muscle insulin receptor function in vitro and in vivo. Am J Physiol Endocrinol Metab 1989; 256: E39-E48.